Abstract: An orthopedic fixation system includes an implant transitionable between a natural shape and an insertion shape and an implant retainer. The implant includes a transition section deformable to move the implant between the natural shape and the insertion shape. The implant includes a first post and a second post protruding therefrom across the transition section. The first post and second post each include an opening therethrough, whereby, when the implant resides in the insertion shape, the opening of the first post and the opening of the second post align. The implant retainer being configured to insert in the openings of the first and second posts when the implant resides in the insertion shape such that the implant retainer interconnects the first post and second post while spanning the transition section, thereby constraining the implant in the insertion shape.

Abstract: The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, L, M, W, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

Abstract: The present invention provides novel polynucleotides encoding LSI-01 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LSI-01 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Abstract: Compounds of formula I its stereoisomers, solvates, and salts, thereof, wherein: a, b, c, d, f, n, m and Ra are defined herein are are inhibitors of calcium channel function, and are useful in treating calcium channel-dependent disorders, including hypertension.